XML 38 R25.htm IDEA: XBRL DOCUMENT v3.26.1
Commitments and Contingencies
9 Months Ended
Mar. 31, 2026
Commitments and Contingencies  
Commitments and Contingencies

19.   Commitments and Contingencies

CRO Agreements

In fiscal years 2025 and 2026, the Company entered into agreements with five contract research organizations (“CROs”) for chemistry, manufacturing, and controls (CMC) development, non-clinical toxicology and related studies to advance IBIO-600 and IBIO-610 towards clinical testing. The Company incurred costs of approximately $1.5 million and $5.9 million for the three and nine months ended March 31, 2026, respectively, and has incurred total costs of approximately $8 million since the projects’ inception. The Company is committed to additional costs totaling approximately $6.2 million as of March 31, 2026.